Skip Navigation LinksIIBR > Covid19


The Israel Institute for Biological Research (IIBR) is leading the Israeli applicative research in a response to the COVID-19 outbreak. As a main goal, IIBR is making advanced R&D efforts in developing the vaccine based on an engineered virus and​ monoclonal neutralizing antibodies treatment for SARS-Cov-2 virus. These vaccine and therapeutic antibodies will provide a state of the art protection for the Israeli population. At the same time, IIBR is performing “Corona” R&D in different aspects of biological safety and protective issues, complex diagnostic and risk assessment. 
IIBR’s contribution is well appreciated among the international scientific community and decision makers.

Prof. Shmuel C. Shapira
Director General IIBR ​